(¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 2ÀÏ : 2021-04-02±³À°ÀÏÀÚ : 2021-04-02
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2021 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2021)-4¿ù 2ÀÏ ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : À±ÁöÇý
¿¬¶ôó : 02-566-6031
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 150,000¿ø
ºñ°í ´ëÇÑÇ÷¾×ÇÐȸ ȸ¿ø £Ü50,000, Æç·Î¿ì/°£È£»ç/¿¬±¸¿ø £Ü30,000 Çлý/Àü°øÀÇ £Ü20,000, ºñȸ¿ø £Ü150,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 09:00~09:30 B-Cell Lymphoma''s New Genomics °í¿µÀÏ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 09:30~10:00 Immuno-Oncology for B-Cell Lymphomas ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 10:00~10:30 Novel Combination Immunochemotherapy beyond CD20 ÀÌÁØÈ£(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 10:30~11:15 Genetic Landscape of Lymphoma and Novel Treatment Approaches Wyndham Hopkins Wilson(National Cancer Institute USA)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 11:30~12:10 When and How to Treat Front-Line Chronic Lymphocytic Leukemia? Susan O¡¯Brien(University of Cambridge USA)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 3 12:40~13:40 Adaptive natural killer cells facilitate effector functions of daratumumab in multiple myeloma Á¶Çö¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 13:55~14:40 The Evolution of Acute Leukemia Diagnostics and Its Place in Treatment Elizabeth Macintyre(The Hôpital Necker-Enfants Malades France)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 14:40~15:10 Outcome of Autologous Transplant in T-Cell Lymphoma: Experience of NIHBT in Vietnam Nguyen Vu Bao Anh(Hanoi Medical University Vietnam)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 15:10~15:40 Subcutaneous Panniculitis-like T-Cell Lymphoma Udomsak Bunworasate(King Chulalongkorn Memorial Hospital Thailand)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 15:40~16:10 Update of Extranodal NK/T-cell Lymphoma: Treatment and Biology ±è¼®Áø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 16:25~16:45 Immunotherapy in AML: From alloSCT towards CAR-T Cell Therapy Charles Craddock(Queen Elizabeth Hospital UK)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 16:45~17:05 The Emerging Role of MRD in AML Gert Ossenkoppele(Amsterdam University The Netherlands)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 17:05~17:30 Therapeutic Potential of ATO to Overcome Resistance of Bcl-2 Inhibitor in AML ÀåÁöÀº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ Room 1 17:30~17:55 MRD in AML Á¶º´½Ä(°¡Å縯ÀÇ´ë)